D.J. St. Germain’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

D.J. St. Germain’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33	Closed	-$23	–	928
2025 Q3	$23	Hold	33	–	–	﹤0.01%	890
2025 Q2	$37	Hold	33	–	–	﹤0.01%	866
2025 Q1	$42	Hold	33	–	–	﹤0.01%	789
2024 Q4	$75	Hold	33	–	–	﹤0.01%	814
2024 Q3	$115	Hold	33	–	–	﹤0.01%	752
2024 Q2	$169	Hold	33	–	–	﹤0.01%	747
2024 Q1	$282	Hold	33	–	–	﹤0.01%	750
2023 Q4	$137	Hold	33	–	–	﹤0.01%	760
2023 Q3	$100	Hold	33	–	–	﹤0.01%	735
2023 Q2	$1.03K	Buy	+33	New	+$1.37K	﹤0.01%	672

D.J. St. Germain's BCLI Position: Q4 2025 in Review

D.J. St. Germain sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2025, closing a stake of 33 shares — an estimated $23 sold.

D.J. St. Germain first reported a position in BCLI in Q2 2023 and held it in 10 quarters. The position peaked at $1.03K in Q2 2023. 0 funds tracked by Wall St. Rank hold BCLI as of Q4 2025.

D.J. St. Germain reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2025 after selling out during the quarter.
D.J. St. Germain sold 33 BRAINSTORM CELL THERAPUTC shares in Q4 2025, an estimated $23.
D.J. St. Germain first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 10 quarters.
D.J. St. Germain's BRAINSTORM CELL THERAPUTC position peaked at $1.03K in Q2 2023.
0 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2025.

Based on D.J. St. Germain's 13F filing for Q4 2025, filed 29 Jan 2026.